Evotec SE stock (DE0005664809): Shares steady as strategic review and analyst views shape sentiment

Evotec SE shares traded in a narrow range on Xetra as investors assessed the German biotech’s ongoing strategic review alongside existing analyst targets and recent price moves on 06/01/2026.

Evotec SE shares showed limited movement on Xetra on 05/31/2026, with the stock around EUR 5.28 as investors weighed the company’s ongoing strategic options against prior quarterly figures and partnership news, according to finanzen.ch as of 05/31/2026.

The Hamburg-based biotech, listed in Germany under the symbol EVT and ISIN DE0005664809, recently initiated a formal strategic review process with Morgan Stanley and Moelis & Company as advisers, a step that has sharpened market focus on potential corporate scenarios, as highlighted by an overview on ad-hoc-news.de referencing the company’s announcement.

On the German market, Evotec SE’s Xetra listing remains the primary venue for domestic investors, with the stock quoted at about EUR 5.27 and up roughly 2.5 percent on 05/30/2026 versus the previous close, based on pricing data from finanzen.net as of 05/30/2026.

The company’s profile as a German biotechnology specialist in drug discovery and development services, combined with its presence on both Xetra and Nasdaq (ticker EVO), keeps it firmly anchored in Germany while also offering international investors access via US trading, as noted by MarketBeat and finanzen.net in late May 2026.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Evotec
• Sector/industry: Biotechnology and drug discovery services
• Headquarters/country: Hamburg, Germany
• Core markets: Europe, North America and selected global pharma and biotech hubs
• Key revenue drivers: Drug discovery alliances, development partnerships and milestone/royalty-bearing partnered pipelines
• Home exchange/listing venue: Xetra (EVT)
• Trading currency: EUR

Evotec SE: core business model

Evotec operates as a contract drug discovery and development partner for pharmaceutical and biotechnology companies, generating revenue primarily by advancing external pipelines through fee-for-service work, milestones and potential royalties tied to partnered assets.

What banks and research houses say about Evotec SE

For the current Monday module, analyst coverage must be viewed using both home-market and international lenses, as several sources aggregate expectations for Evotec SE but public, named-bank research notes with full details are not always freely accessible in German filings.

According to MarketBeat, which tracks Nasdaq-listed Evotec under the ticker EVO, four Wall Street analysts had a "Moderate Buy" consensus on the stock with an average 12-month price target of USD 7.00 as of 05/29/2026, versus a closing price of USD 3.07 on Nasdaq on 05/29/2026, indicating notable upside potential in that specific data set, as summarized by MarketBeat as of 05/29/2026.

A separate overview from finanzen.ch dated 05/2026 notes that analysts following the Xetra-listed shares see an average target price of about EUR 7.25 compared with a contemporaneous Xetra level of roughly EUR 5.28, implying a gap between current trading and the price expectations compiled in that Swiss financial portal’s analyst survey.

No verified analyst coverage was identified at the time of publication.

Conclusion

Evotec SE’s share price on Xetra has recently moved in a narrow band as the German biotech’s strategic review and existing analyst expectations are digested by the market. The contrast between current trading levels and the average price targets compiled by MarketBeat and finanzen.ch underlines how much weight investors place on the company’s ability to convert its partnered discovery platforms into future cash flows and potential royalties. Upcoming updates on the strategic process and any changes in analyst coverage are likely to be watched closely by both domestic and international shareholders.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.